You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
Researchers found an increased risk for diabetes among men being treated with androgen deprivation therapy.
Regardless of age, men undergoing prostate cancer treatment via androgen deprivation therapy have an increased risk of diabetes and cardiovascular disease. A study published in early December by Brigham and Women's Hospital in Boston noted that although androgen deprivation therapy has been associated with a higher risk of diabetes and cardiovascular problems in older men, this is the first time the connection has been noted among men of all ages.
Researchers at the hospital tracked 38,000 men of all ages who had been diagnosed by the Veterans Healthcare Administration as having local or regional prostate cancer. The four-year study, which ran from January 2001 through December 2004, sought evidence that androgen deprivation therapy, using gonadotropin-releasing hormone agonists, increases disease risk among the men. One of the advantages of the large sampling, the researchers noted, was that many of the patients studied were men under the age of 55 and over the age of 75-the age range within which prostate problems most commonly fall.
The researchers found a statistically significant increased risk for diabetes among men being treated with GnRH agonists: 159.4 events per 1,000 person years for men undergoing the therapy, versus 87.5 events per 1,000 person years for men taking no androgen deprivation therapy.
When publishing their findings in the December 7 issue of the Journal of the National Cancer Institute,* the researchers said that additional study is required to more accurately identify the groups that run the highest risk from androgen deprivation therapy and to find ways to mitigate or overcome its negative effects while providing an effective tool against prostate cancer.
(*The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute.)
* * *
Source: http://www.eurekalert.org/pub_releases/2009-12/jotn-hrf120309.php
Categories: Diabetes, Diabetes, Heart Care & Heart Disease, Type 2 Issues
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...